<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9231926</article-id><article-id pub-id-type="pmc">2223945</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>J. F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jeng</surname><given-names>J. E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chuang</surname><given-names>L. Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>M. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>M. S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>W. Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hsieh</surname><given-names>M. Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Z. Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>J. H.</given-names></name></contrib></contrib-group><aff>Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>2</issue><fpage>244</fpage><lpage>250</lpage><abstract><p>To assess the clinical relevance of transforming growth factor-beta1 (TGF-beta1) in hepatocellular carcinoma (HCC), urinary TGF-beta1 and serum alpha-fetoprotein (AFP) were determined in 94 patients with cirrhotic HCC, 94 age- and sex-matched patients with cirrhosis alone and 50 healthy adults. TGF-beta1 level in HCC was higher than in cirrhosis alone or in healthy controls (each P = 0.0001). There is an inverse correlation between TGF-beta1 and AFP levels (r = -0.292, P = 0.004). Significantly higher TGF-beta1 level was found in HCC patients with worsening Child-Pugh stages, diffuse HCC, tumour size &#x0003e; 3 cm, multilobular tumour and AFP &#x0003c; or = 20 ng ml(-1). TGF-beta1 level decreased after complete treatment with transcatheter arterial chemoembolization (P = 0.0001). The median survival in HCC patients with raised TGF-beta1 was shorter than those with normal TGF-beta1 (P = 0.018). Multivariate analysis indicated that TGF-beta1 and AFP were significantly correlated with the presence of HCC. In addition, TGF-beta1 could be used as a diagnostic marker for HCC, particularly in tumours with low AFP production. In conclusion, elevated urinary TGF-beta1 level is a tumour marker and predictor of poor survival for cirrhotic HCC.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00166-0108.tif" xlink:title="scanned-page" xlink:role="244" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00166-0109.tif" xlink:title="scanned-page" xlink:role="245" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00166-0110.tif" xlink:title="scanned-page" xlink:role="246" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00166-0111.tif" xlink:title="scanned-page" xlink:role="247" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00166-0112.tif" xlink:title="scanned-page" xlink:role="248" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00166-0113.tif" xlink:title="scanned-page" xlink:role="249" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00166-0114.tif" xlink:title="scanned-page" xlink:role="250" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

